# The Critical Role of Nutritional and Procedural Factors in CTO-PCI Patient Prognosis

**Authors:** Gürkan Karaca, Ahmet Ekmekci, Ali Kimiaei, Seyedehtina Safaei, Aziz İnan Çelik, Metin Çağdaş

PMC · DOI: 10.3390/life16020338 · Life · 2026-02-15

## TL;DR

This study shows that both the complexity of a heart procedure and a patient's nutritional health strongly affect outcomes in patients undergoing CTO-PCI.

## Contribution

The study introduces the combined use of procedural complexity scores and nutritional status (PNI) to improve risk prediction in CTO-PCI patients.

## Key findings

- Lower Prognostic Nutritional Index (PNI) and higher lesion complexity scores were linked to worse outcomes in CTO-PCI patients.
- A PNI cut-off of 46 predicted mortality with 70.6% sensitivity and 75.2% specificity.
- LVEF, J-CTO score, and PNI were identified as independent predictors of mortality in multivariable analysis.

## Abstract

(1) Background: Chronic total occlusion percutaneous coronary intervention (CTO-PCI) is a complex, high-risk procedure compared to standard percutaneous coronary intervention (PCI). Scoring systems such as the Japanese Chronic Total Occlusion (J-CTO), European Chronic Total Occlusion (EuroCTO), and Prospective Global Registry for the Study of Chronic Total Occlusion Intervention (PROGRESS-CTO) evaluate lesion difficulty and predict outcomes. Nutritional status, measured by the Prognostic Nutritional Index (PNI), may also affect procedural success and long-term survival. The objective of this study was to evaluate the combined impact of procedural complexity and nutritional status on the clinical outcomes of patients undergoing CTO-PCI. (2) Methods: We analyzed 118 patients undergoing CTO-PCI between May 2021 and March 2022. Procedural complexity was assessed using the J-CTO, EuroCTO, and PROGRESS-CTO scores, while nutritional status was evaluated using the PNI. Primary outcomes included all-cause mortality and repeat revascularization, which were analyzed using Cox proportional hazards regression and Kaplan–Meier survival analyses. (3) Results: Adverse outcomes occurred in 25 patients (mortality: 17; revascularization: 8). Patients with adverse outcomes had significantly lower left ventricular ejection fraction (LVEF) (46 ± 13.7% vs. 52.1 ± 10.5%, p < 0.001), lower PNI (p < 0.001), and higher J-CTO, EuroCTO, and PROGRESS-CTO scores (all p < 0.05). A PNI cut-off value of 46 predicted mortality with a sensitivity of 70.6% and specificity of 75.2% (area under the curve [AUC] = 0.739, p = 0.001). Multivariable analysis identified LVEF (hazard ratio [HR] 0.966, p = 0.036), J-CTO score (HR 1.598, p = 0.027), and PNI (HR 0.925, p = 0.022) as independent predictors of mortality. (4) Conclusion: Both procedural complexity and nutritional status significantly influence outcomes following CTO-PCI. Incorporating PNI together with procedural complexity scores into pre-procedural assessments may enhance risk stratification and optimize patient management.

## Full-text entities

- **Genes:** CRP (C-reactive protein) [NCBI Gene 1401] {aka PTX1}, SLC17A5 (solute carrier family 17 member 5) [NCBI Gene 26503] {aka AST, ISSD, NSD, SD, SIALIN, SIASD}, ALB (albumin) [NCBI Gene 213] {aka FDAHT, HSA, PRO0883, PRO0903, PRO1341}
- **Diseases:** stent thrombosis (MESH:D013927), atherosclerosis (MESH:D050197), PNI (MESH:D044342), cardiac death (MESH:D003643), CTO (MESH:D001157), hypertension (MESH:D006973), cardiovascular disease (MESH:D002318), myocardial infarction (MESH:D009203), coronary artery occlusion (MESH:D054059), heart failure (MESH:D006333), cardiac (MESH:D006331), PROGRESS (MESH:D018450), CTO lesion (MESH:D002908), tortuosity (MESH:C565942), inflammation (MESH:D007249), complication (MESH:D008107), injury to (MESH:D014947), disease (MESH:D004194), dyslipidemia (MESH:D050171), calcification (MESH:D002114), diabetes mellitus (MESH:D003920), STEMI (MESH:D000072657), left ventricular dysfunction (MESH:D018487), stroke (MESH:D020521), chronic obstructive pulmonary disease (MESH:D029424), stenosis (MESH:D003251), nutritional deficits (MESH:D009748)
- **Chemicals:** clopidogrel (MESH:D000077144), ACEi (-), ticagrelor (MESH:D000077486), prasugrel (MESH:D000068799), MRA (MESH:C502936), aspirin (MESH:D001241), cholesterol (MESH:D002784)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12941386/full.md

## Figures

4 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12941386/full.md

## References

29 references — full list in the complete paper: https://tomesphere.com/paper/PMC12941386/full.md

---
Source: https://tomesphere.com/paper/PMC12941386